Pharmaceutical

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

Sep 23, 2023 - 20:00
Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate
According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.
Read the original article

Tags:

Previous Article

Over half of world’s population not covered by essential healthcare services

Next Article

JURA Bio and Syena partner to develop TCR-based therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT readers on diagnostic tests, marijuana regulation, and pediatric oncology

Opinion: STAT readers on diagnostic tests, marijuana re...

Dec 9, 2023

STAT+: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in

STAT+: After decade-long dispute over CRISPR-Cas9, Edit...

Dec 13, 2023

STAT+: Key questions (and answers) about the historic approval of a CRISPR-based medicine

STAT+: Key questions (and answers) about the historic a...

Nov 19, 2023